文献速递消化道肿瘤放疗

内镜黏膜下剥离术联合放化疗治疗表浅性食管癌:新方法的选择

Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach.
PubMed 文献 · Radiat Oncol · 2018-12-14

这项回顾性研究纳入2014至2017年接受内镜黏膜下剥离术(ESD)后放化疗(CRT)的临床T1b期无远处转移表浅性食管癌患者16例,与2008至2015年接受ESD后食管切除术的16例历史对照比较。CRT组2年总生存率100%,局部区域控制全部达成,两组2年无病生存率分别为88%和100%,无显著差异。作者认为该新方法安全有效,可能为临床T1b期患者提供非手术治疗选择。

要点

  • CRT组16例患者放疗均完成,≥3级非血液学不良事件发生率为6%。
  • CRT组2年总生存率100%,全部患者实现局部区域控制。
  • CRT组与食管切除术组2年无病生存率分别为88%和100%,无显著差异。

核心结论

  • 作者认为其新方法安全有效,在局部区域控制方面表现良好,可能为临床T1b期肿瘤患者提供非手术治疗选择。

研究设计与样本

  • 回顾性研究,纳入2014至2017年接受ESD后CRT的临床T1b期无 apparent 转移患者(CRT组),与2008至2015年连续接受ESD后食管切除术的历史对照组(食管切除术组)比较无病生存结局。
  • 共分析32例患者,CRT组16例,食管切除术组16例(分期相似)。

主要发现

  • CRT组所有患者均完成放疗,≥3级非血液学不良事件发生率为6%。
  • CRT组2年总生存率为100%,全部患者实现局部区域控制。
  • CRT组与食管切除术组2年无病生存率分别为88%和100%,无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The standard treatment for superficial esophageal cancer (SEC) involving muscularis mucosal (T1a-MM) or submucosal (T1b) invasion has been the surgical resection of the esophagus. However, esophagectomy with extended lymph node dissection is highly invasive. Recent reports have shown that endoscopic submucosal dissection (ESD) followed by chemoradiotherapy (CRT) has promising results and might become a new therapeutic approach. This retrospective study aimed to elucidate the efficacy and safety of this new treatment. METHODS: Patients with clinical stage T1b tumor without apparent metastasis treated with ESD followed by CRT from 2014 to 2017 (the CRT group) were included. The outcomes on disease-free survival (DFS) of this group were compared with those of consecutive patients in a historical control group who underwent ESD followed by esophagectomy (the esophagectomy group) between 2008 and 2015. RESULTS: Of 32 patients analyzed, 16 were in the CRT group and 16 with similar stage cancer were in the esophagectomy group. Radiotherapy was completed in all patients, and the incidence of grade ≥ 3 nonhematologic adverse events was 6%. The 2-year overall survival rates were 100%, and locoregional control was achieved in all patients in the CRT group, and the 2-year DFS rates were 88 and 100% for the CRT and esophagectomy groups, respectively, without significant differences. CONCLUSIONS: Our data confirmed our new approach as being safe and effective for locoregional control and may provide a nonsurgical treatment option for patients with clinical stage T1b tumors.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Suzuki G, Yamazaki H, Aibe N, et al. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach. Radiat Oncol. 2018. PMID: 30547811. doi:10.1186/s13014-018-1195-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。